12:00 AM
 | 
Aug 07, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Beta LT: Phase I/II

LifeTime said that in two Phase I/II trials in Canada, a total of 14 patients received the target dose of Beta LT for up to 1 year and showed no local or systemic...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >